EU antitrust regulators are investigating whether French utility EDF’s bid for a majority stake in Areva’s nuclear arm would hit competition and innovation in the nuclear services market, a person familiar with the matter said on Wednesday.
The European Commission is currently examining a deal that would see state-controlled EDF acquire 51 to 75 percent of Areva NP, which designs, makes and services nuclear reactors. The sale is part of loss-making Areva’s rescue plan.
The EU competition enforcer will rule by May 29 whether to clear the deal with or without conditions, or whether to open a full-scale, four-month investigation.
The Commission has asked rivals and customers how the deal will affect prices, innovation and quality, the source said, speaking on condition of anonymity due to the sensitivity of the matter.
Innovation has become a key focus for regulators seeking to ensure the pipeline of key products and technologies will continue to flow after companies are snapped up by rivals.
Regulators also want to know if other suppliers would be able to step in in the event New Areva NP decides only to provide services to EDF once the deal is completed, the source said.
Full Content: Zone Bourse
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
BCLP Strengthens Healthcare and Antitrust Litigation Practice
May 19, 2025 by
CPI
Italy Fines AI Chatbot Maker Replika €5 Million Over Privacy Violations
May 19, 2025 by
CPI
Germany’s Antitrust Chief: EU-US Tech Policy Divide Is Mostly Rhetoric
May 19, 2025 by
CPI
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas